{
    "topic": "coronavirus",
    "source": "Newsmax (News)",
    "bias": 2,
    "url": "https://www.newsmax.com/world/globaltalk/elite-executives-gamaleya/2020/07/20/id/977978/",
    "title": "Russian Elite Given Experimental COVID-19 Vaccine Since April",
    "date": "2020-07-20",
    "authors": "Stepan Kravchenko, Yuliya Fedorinova, Ilya Arkhipov",
    "content": "Scores of Russia \u2019 s business and political elite have been given early access to an experimental vaccine against Covid-19 , according to people familiar with the effort , as the country races to be among the first to develop an inoculation .\nTop executives at companies including aluminum giant United Co. Rusal , as well as billionaire tycoons and government officials began getting shots developed by the state-run Gamaleya Institute in Moscow as early as April , the people said . They declined to be identified as the information isn \u2019 t public .\nThe Gamaleya vaccine , financed by the state-run Russian Direct Investment Fund and backed by the Defense Ministry , last week completed a phase 1 trial involving military personnel . The institute hasn \u2019 t published results for the study , which involved about 40 people , but has begun the next stage of testing with a larger group .\nGamaleya \u2019 s press office couldn \u2019 t be reached immediately for comment . Kremlin spokesman Dmitry Peskov , who recovered from Covid-19 after being hospitalized with the virus in May , said he doesn \u2019 t know the names of anyone who \u2019 s received the institute \u2019 s vaccine .\nAsked on a conference call with reporters on Monday if President Vladimir Putin had taken it , Peskov said : \u201c It probably wouldn \u2019 t be a good idea to use an uncertified vaccine on the head of state , \u201d adding that he wasn \u2019 t aware of other officials trying it .\nPeskov \u2019 s comments followed a Health Ministry statement that said only participants in Gamaleya \u2019 s trials are currently eligible for the jabs .\nWhile the new shots are \u201c safe \u201d because they \u2019 re based on proven vaccines for other diseases , their effectiveness has yet to be determined , according to Sergei Netesov , a former executive at Vector , a state-run virology center in Novosibirsk , Siberia , that \u2019 s also working on an inoculation .\n\u201c Those who take it do so at their own risk , \u201d Netesov said .\nRussia has reported more than 750,000 cases of Covid-19 , the fourth-largest total in the world , and Gamaleya \u2019 s program is on a faster track than many developers in the West . RDIF chief Kirill Dmitriev said last week phase 3 trials will start Aug. 3 and include thousands of people in Russia , Saudi Arabia and the United Arab Emirates , with the vaccine distributed nationally as early as September . Western researchers typically run phase 3 trials for months to better understand safety and effectiveness .\nGamaleya \u2019 s candidate is a so-called viral vector vaccine based on human adenovirus \u2014 a common cold virus \u2014 fused with the spike protein of SARS CoV-2 to stimulate an immune response . It is similar to a vaccine being developed by China \u2019 s CanSino Biologics , which is already in phase 2 trials with plans for more in Canada .\nCanada was among the countries -- along with the U.S. and U.K. -- that last week accused Russian government-backed hackers of trying to steal secrets of their Covid-19 vaccine research . Russian officials deny the allegations .\nThe program under which well-connected Russians have been given the chance to volunteer for doses of the experimental vaccine is legal but kept under wraps to avoid a crush of potential participants , according to a researcher familiar with the effort . He said several hundred people have been involved . Bloomberg confirmed dozens who have had the shots but none would allow their names to be published .\nIt \u2019 s not clear how participants are selected and they aren \u2019 t part of the official studies , though they are monitored and their results logged by the institute . Patients usually get the shots -- two are needed to produce an immune response that\nGamaleya says will last for about two years -- at a Moscow clinic connected to the institute . Participants aren \u2019 t charged a fee and sign releases confirming they know the risks involved .\nDmitriev of the RDIF said he and his family had taken the shots and noted that a significant number of other volunteers have also been given the opportunity . He declined to provide further details . The Gamaleya Institute said it vaccinated its director , as well as the team working on the trial , when it started . In May , state-controlled Sberbank recruited volunteers among employees to take the jabs .\nOne senior executive who \u2019 s been inoculated said he experienced no side effects . He said the health risks are worth being able to resume normal life , both personal and professional . Other takers reported experiencing fevers and muscle aches after getting the shots .\nSeveral managers in the Moscow offices of Rusal , which relies on Gamaleya \u2019 s Ebola vaccine to maintain operations in the West African country of Guinea , have already taken the institute \u2019 s Covid-19 shots , people familiar with the matter said . Fertilizer maker PhosAgro PJSC is among the corporations who \u2019 ve been invited to follow suit , other people said . Spokespeople for Rusal and Phosagro declined to comment .\nSome executives at major companies said they turned down the offer on health concerns . One tycoon said he decided against participating after his doctor told him it would take at least a year to assess the new vaccine \u2019 s risks .\nInitial results from CanSino \u2019 s trial showed its adenovirus-based vaccine had a diminished effect in some people who had a pre-existing immunity to that pathogen . RDIF \u2019 s Dmitriev said researchers in Russia are testing two different types of adenovirus vectors in order to reduce the chances of pre-existing immunity reducing the cocktail \u2019 s effectiveness .\nGamaleya chief Alexander Ginzbur said he wasn \u2019 t aware of any government officials or business leaders taking his institute \u2019 s vaccine , according to Interfax .",
    "content_original": "Scores of Russia\u2019s business and political elite have been given early access to an experimental vaccine against Covid-19, according to people familiar with the effort, as the country races to be among the first to develop an inoculation.\n\nTop executives at companies including aluminum giant United Co. Rusal, as well as billionaire tycoons and government officials began getting shots developed by the state-run Gamaleya Institute in Moscow as early as April, the people said. They declined to be identified as the information isn\u2019t public.\n\nThe Gamaleya vaccine, financed by the state-run Russian Direct Investment Fund and backed by the Defense Ministry, last week completed a phase 1 trial involving military personnel. The institute hasn\u2019t published results for the study, which involved about 40 people, but has begun the next stage of testing with a larger group.\n\nGamaleya\u2019s press office couldn\u2019t be reached immediately for comment. Kremlin spokesman Dmitry Peskov, who recovered from Covid-19 after being hospitalized with the virus in May, said he doesn\u2019t know the names of anyone who\u2019s received the institute\u2019s vaccine.\n\nAsked on a conference call with reporters on Monday if President Vladimir Putin had taken it, Peskov said: \u201cIt probably wouldn\u2019t be a good idea to use an uncertified vaccine on the head of state,\u201d adding that he wasn\u2019t aware of other officials trying it.\n\nPeskov\u2019s comments followed a Health Ministry statement that said only participants in Gamaleya\u2019s trials are currently eligible for the jabs.\n\nWhile the new shots are \u201csafe\u201d because they\u2019re based on proven vaccines for other diseases, their effectiveness has yet to be determined, according to Sergei Netesov, a former executive at Vector, a state-run virology center in Novosibirsk, Siberia, that\u2019s also working on an inoculation.\n\n\u201cThose who take it do so at their own risk,\u201d Netesov said.\n\nRussia has reported more than 750,000 cases of Covid-19, the fourth-largest total in the world, and Gamaleya\u2019s program is on a faster track than many developers in the West. RDIF chief Kirill Dmitriev said last week phase 3 trials will start Aug. 3 and include thousands of people in Russia, Saudi Arabia and the United Arab Emirates, with the vaccine distributed nationally as early as September. Western researchers typically run phase 3 trials for months to better understand safety and effectiveness.\n\nGamaleya\u2019s candidate is a so-called viral vector vaccine based on human adenovirus \u2014 a common cold virus \u2014 fused with the spike protein of SARS CoV-2 to stimulate an immune response. It is similar to a vaccine being developed by China\u2019s CanSino Biologics, which is already in phase 2 trials with plans for more in Canada.\n\nCanada was among the countries -- along with the U.S. and U.K. -- that last week accused Russian government-backed hackers of trying to steal secrets of their Covid-19 vaccine research. Russian officials deny the allegations.\n\nExperimental Vaccine\n\nThe program under which well-connected Russians have been given the chance to volunteer for doses of the experimental vaccine is legal but kept under wraps to avoid a crush of potential participants, according to a researcher familiar with the effort. He said several hundred people have been involved. Bloomberg confirmed dozens who have had the shots but none would allow their names to be published.\n\nIt\u2019s not clear how participants are selected and they aren\u2019t part of the official studies, though they are monitored and their results logged by the institute. Patients usually get the shots -- two are needed to produce an immune response that\n\nGamaleya says will last for about two years -- at a Moscow clinic connected to the institute. Participants aren\u2019t charged a fee and sign releases confirming they know the risks involved.\n\nDmitriev of the RDIF said he and his family had taken the shots and noted that a significant number of other volunteers have also been given the opportunity. He declined to provide further details. The Gamaleya Institute said it vaccinated its director, as well as the team working on the trial, when it started. In May, state-controlled Sberbank recruited volunteers among employees to take the jabs.\n\nOne senior executive who\u2019s been inoculated said he experienced no side effects. He said the health risks are worth being able to resume normal life, both personal and professional. Other takers reported experiencing fevers and muscle aches after getting the shots.\n\nVaccine Race\n\nSeveral managers in the Moscow offices of Rusal, which relies on Gamaleya\u2019s Ebola vaccine to maintain operations in the West African country of Guinea, have already taken the institute\u2019s Covid-19 shots, people familiar with the matter said. Fertilizer maker PhosAgro PJSC is among the corporations who\u2019ve been invited to follow suit, other people said. Spokespeople for Rusal and Phosagro declined to comment.\n\nSome executives at major companies said they turned down the offer on health concerns. One tycoon said he decided against participating after his doctor told him it would take at least a year to assess the new vaccine\u2019s risks.\n\nInitial results from CanSino\u2019s trial showed its adenovirus-based vaccine had a diminished effect in some people who had a pre-existing immunity to that pathogen. RDIF\u2019s Dmitriev said researchers in Russia are testing two different types of adenovirus vectors in order to reduce the chances of pre-existing immunity reducing the cocktail\u2019s effectiveness.\n\nGamaleya chief Alexander Ginzbur said he wasn\u2019t aware of any government officials or business leaders taking his institute\u2019s vaccine, according to Interfax.",
    "source_url": "www.newsmax.com",
    "bias_text": "right",
    "ID": "lmWIGHpP0mWVFG4L"
}